Themis Medicare Limited (THEMISMED.BO)
INR 127.95
(6.14%)
INR 127.95
(6.14%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 562.6 Million INR | -43.37% |
| 2022 | 789.55 Million INR | -18.25% |
| 2021 | 1.02 Billion INR | 82.89% |
| 2020 | 531.15 Million INR | 31.4% |
| 2019 | 391.21 Million INR | 696.48% |
| 2018 | 72.14 Million INR | -80.13% |
| 2017 | 306.12 Million INR | -17.85% |
| 2016 | 356.83 Million INR | -10.55% |
| 2015 | 413.44 Million INR | 39.03% |
| 2014 | 286.35 Million INR | 5.49% |
| 2013 | 271.43 Million INR | 61.53% |
| 2012 | 168.04 Million INR | 230.83% |
| 2011 | -128.43 Million INR | -143.86% |
| 2010 | 292.86 Million INR | -20.45% |
| 2009 | 368.16 Million INR | 167.86% |
| 2008 | 137.44 Million INR | -61.47% |
| 2007 | 356.71 Million INR | 34.54% |
| 2006 | 265.12 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 226.88 Million INR | -24.71% |
| 2024 Q1 | 291.75 Million INR | 189.88% |
| 2023 Q2 | 190.66 Million INR | -31.99% |
| 2023 Q3 | 139.99 Million INR | -26.58% |
| 2023 Q4 | 92.95 Million INR | -33.6% |
| 2023 FY | - INR | -43.37% |
| 2023 Q1 | 280.34 Million INR | 97.86% |
| 2022 Q4 | 141.68 Million INR | -36.74% |
| 2022 Q1 | 268.14 Million INR | 63.6% |
| 2022 FY | - INR | -18.25% |
| 2022 Q2 | 275.65 Million INR | 2.8% |
| 2022 Q3 | 223.98 Million INR | -18.74% |
| 2021 Q4 | 163.9 Million INR | -24.6% |
| 2021 Q1 | 452.88 Million INR | 249.42% |
| 2021 FY | - INR | 82.89% |
| 2021 Q2 | 278.29 Million INR | -38.55% |
| 2021 Q3 | 217.36 Million INR | -21.89% |
| 2020 Q4 | 129.61 Million INR | -31.04% |
| 2020 Q3 | 187.95 Million INR | 31.42% |
| 2020 FY | - INR | 31.4% |
| 2020 Q1 | 147.66 Million INR | 4.61% |
| 2020 Q2 | 143.01 Million INR | -3.15% |
| 2019 Q2 | 65.56 Million INR | -35.93% |
| 2019 Q4 | 141.16 Million INR | -8.23% |
| 2019 Q1 | 102.32 Million INR | 227.69% |
| 2019 FY | - INR | 696.48% |
| 2019 Q3 | 153.83 Million INR | 134.64% |
| 2018 Q3 | 44.03 Million INR | 6.86% |
| 2018 Q2 | 41.2 Million INR | -22.28% |
| 2018 Q1 | 53.01 Million INR | -49.3% |
| 2018 FY | - INR | -80.13% |
| 2018 Q4 | -80.13 Million INR | -282.0% |
| 2017 Q4 | 104.58 Million INR | 55.55% |
| 2017 FY | - INR | -17.85% |
| 2017 Q2 | 118.75 Million INR | 0.0% |
| 2017 Q3 | 67.23 Million INR | -43.39% |
| 2016 Q3 | 124.86 Million INR | 209.62% |
| 2016 FY | - INR | -10.55% |
| 2016 Q2 | 40.32 Million INR | -67.17% |
| 2016 Q1 | 122.83 Million INR | 27.69% |
| 2016 Q4 | 86.37 Million INR | -30.82% |
| 2015 Q1 | 112.44 Million INR | 74.38% |
| 2015 Q3 | 99.21 Million INR | -18.14% |
| 2015 Q4 | 96.2 Million INR | -3.04% |
| 2015 FY | - INR | 39.03% |
| 2015 Q2 | 121.2 Million INR | 7.79% |
| 2014 Q3 | 86.09 Million INR | 50.19% |
| 2014 FY | - INR | 5.49% |
| 2014 Q2 | 57.32 Million INR | 0.0% |
| 2014 Q4 | 64.48 Million INR | -25.1% |
| 2013 FY | - INR | 61.53% |
| 2012 Q1 | 57.95 Million INR | 0.0% |
| 2012 FY | - INR | 230.83% |
| 2012 Q3 | 1.2 Million INR | -97.93% |
| 2012 Q2 | 58.39 Million INR | 0.75% |
| 2012 Q4 | 47.07 Million INR | 3803.07% |
| 2011 FY | - INR | -143.86% |
| 2010 FY | - INR | -20.45% |
| 2009 FY | - INR | 167.86% |
| 2008 FY | - INR | -61.47% |
| 2007 FY | - INR | 34.54% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 94.15% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 99.089% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 91.802% |
| Granules India Limited | 8.6 Billion INR | 93.461% |
| Indoco Remedies Limited | 2.64 Billion INR | 78.746% |
| Achyut Healthcare Limited | 524 Thousand INR | -107267.748% |
| Ajanta Pharma Limited | 12.56 Billion INR | 95.523% |
| Alkem Laboratories Limited | 24.19 Billion INR | 97.675% |
| Alpa Laboratories Limited | 86.12 Million INR | -553.23% |
| Brooks Laboratories Limited | 41.72 Million INR | -1248.272% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 76.128% |
| Bajaj HealthCare Limited | 444.51 Million INR | -26.566% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 61.961% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 99.363% |
| Eris Lifesciences Limited | 6.98 Billion INR | 91.947% |
| FDC Limited | 4.4 Billion INR | 87.218% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 95.04% |
| Gufic Biosciences Limited | 1.48 Billion INR | 61.998% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 91.801% |
| Ipca Laboratories Limited | 13.29 Billion INR | 95.77% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -73.934% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 780.077% |
| Lasa Supergenerics Limited | -65.08 Million INR | 964.485% |
| Laurus Labs Limited | 8 Billion INR | 92.973% |
| Lupin Limited | 36.96 Billion INR | 98.478% |
| Mankind Pharma Limited | 28.09 Billion INR | 97.997% |
| Medicamen Biotech Limited | 245.66 Million INR | -129.019% |
| Medico Remedies Limited | 150.37 Million INR | -274.129% |
| Megasoft Limited | 284.73 Million INR | -97.592% |
| NATCO Pharma Limited | 18.79 Billion INR | 97.007% |
| Piramal Pharma Limited | 13.05 Billion INR | 95.691% |
| RPG Life Sciences Limited | 1.28 Billion INR | 56.098% |
| Sigachi Industries Limited | 883.39 Million INR | 36.313% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.593% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 87.971% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -30.755% |
| Unichem Laboratories Limited | 742.35 Million INR | 24.213% |
| Wanbury Limited | 985.49 Million INR | 42.911% |
| Windlas Biotech Limited | 781.72 Million INR | 28.03% |
| ZIM Laboratories Limited | 462.09 Million INR | -21.751% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.999% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 115.078% |
| Divi's Laboratories Limited | 25.43 Billion INR | 97.788% |
| Hester Biosciences Limited | 539.47 Million INR | -4.289% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 81.336% |
| Amrutanjan Health Care Limited | 682.53 Million INR | 17.571% |
| Bal Pharma Limited | 345.59 Million INR | -62.795% |
| Strides Pharma Science Limited | 3.76 Billion INR | 85.056% |
| Venus Remedies Limited | 711.8 Million INR | 20.96% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 85.609% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 64.023% |
| Shilpa Medicare Limited | 2.58 Billion INR | 78.261% |
| Aarti Drugs Limited | 3.24 Billion INR | 82.682% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 78.416% |
| Suven Life Sciences Limited | -992.78 Million INR | 156.67% |
| Ind-Swift Limited | 1.06 Billion INR | 47.176% |
| Valiant Laboratories Limited | 12.73 Million INR | -4316.414% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 93.973% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 119.937% |
| Hikal Limited | 2.69 Billion INR | 79.103% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 98.393% |
| Sequent Scientific Limited | 549.8 Million INR | -2.329% |
| Novartis India Limited | 1.26 Billion INR | 55.676% |
| Wockhardt Limited | 1.08 Billion INR | 47.907% |
| Jubilant Pharmova Limited | 8 Billion INR | 92.973% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -4207.204% |
| Neuland Laboratories Limited | 4.74 Billion INR | 88.151% |
| Morepen Laboratories Limited | 1.72 Billion INR | 67.403% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -95.74% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -221.589% |